ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AAZ Anglo Asian Mining Plc

88.50
1.90 (2.19%)
Last Updated: 09:31:18
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Anglo Asian Mining Plc LSE:AAZ London Ordinary Share GB00B0C18177 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.90 2.19% 88.50 85.00 92.00 88.50 83.50 83.50 92,265 09:31:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Miscellaneous Metal Ores,nec 45.86M -24.24M -0.2122 -3.93 98.93M
Anglo Asian Mining Plc is listed in the Miscellaneous Metal Ores sector of the London Stock Exchange with ticker AAZ. The last closing price for Anglo Asian Mining was 86.60p. Over the last year, Anglo Asian Mining shares have traded in a share price range of 36.50p to 89.50p.

Anglo Asian Mining currently has 114,242,024 shares in issue. The market capitalisation of Anglo Asian Mining is £98.93 million. Anglo Asian Mining has a price to earnings ratio (PE ratio) of -3.93.

Anglo Asian Mining Share Discussion Threads

Showing 72276 to 72300 of 147975 messages
Chat Pages: Latest  2895  2894  2893  2892  2891  2890  2889  2888  2887  2886  2885  2884  Older
DateSubjectAuthorDiscuss
28/4/2020
08:20
Is the seller done AT DDDD?
jbe81
28/4/2020
08:18
Yep, Russian too Mr Roper, Chinese, Nigerian, anywhere ending in ‘stan’ etc etc!
bumpa33
28/4/2020
08:17
It really isn’t their biggest cost.
People are. By far.
We’re not going to see costs decline by anything like the degree the oil price has.

jbravo2
28/4/2020
07:56
ALTN still in orbit mode.

Results imminent and not likely to be earth shattering because it's all about the forward looking statement post their recent ramp up of nice new impressive mining equipment and how that changes the numbers going forward.

IMHO

ODR

onedayrodders
28/4/2020
07:52
I think most people are unhappy about the way the MM's are treating our company with a stupid spread. When you look at greatland gold and they have a spread of just 2.3% compared to here at 7.69%.
No one is really unhappy with the management.
I can understand people not being happy with the share price right now, because even waiting for news,we have seen the gold price rise and the biggest expense for a mining company, oil half in price.

gold finger 1
28/4/2020
07:52
agreed Bumpa, added to cv19 watch list, let's see,,,,, nuts if it does rocket on that,,,, LOL Cheers Wan :-)

btw the first oil and gas producer in the list LOL LOL

wanobi
28/4/2020
07:51
Morning Wan you’re welcome.

SIE frustration maybe, at trying to make himself heard ha

riggerbeautz
28/4/2020
07:50
I know what you mean, bumpa. There was quite a few shockers back in the day. I made an exception for plus. I have a similar phobia on Russian stocks, only one rns away from a wtf moment.
mr roper
28/4/2020
07:47
Unfortunately a deep mistrust of Israeli companies remains to this day, from the spate of frauds/junk listing back in the mid noughties.

ZEN - if that thing goes up on THAT RNS then we’re officially in the lunatic phase of all this cv-19 thing.

bumpa33
28/4/2020
07:41
Great links Rb, just got through them both, the PM one - very interesting indeed, many thanx again for posting them, cheers Wan :-)
wanobi
28/4/2020
07:33
PLUs500 smacks it out the park with another top notch trading update.
mr roper
28/4/2020
07:28
An article neatly summing up why ORPH is a candidate for the CV19 bingo game. It has other strings to its bow but the viral test side and the universal flu vaccine are probably the best bets in this environment. The chairman and very large share holder Cathal Freil's plan remains to sell the company this year at at least 3 times current share price, that's a longer story.

hxxps://www.vennlifesciences.com/inside-stories-of-coronavirus-battlers-aerogen-hibergene-open-orphan-and-nearform/

Open Orphan
Cathal Friel, the chairman of Open Orphan, calls hVivo his “lucky acquisition”. HVivo specialises in viral study models and testing the efficacy of vaccines. The company owns a 24-bedroom quarantine clinic in London.
The AIM-quoted Open Orphan bought hVivo “because it looked cheap”, says Friel. About £113m (€130m) has been invested in the clinic, viral testing models and a universal flu vaccine. While structured as a merger, Open Orphan in effect bought hVivo for £13m. It was an “unloved company” in an unfashionable corner of the pharma services sector, according to Friel — but not any more.

“In truth, in the past number of years there hasn’t been a lot of money spent on developing vaccines — it’s been all talk and no action,” he says. “In the past six weeks, suddenly, being a world leader in viral studies and testing has become a very interesting place.”

Last week Open Orphan announced its involvement in an antiviral treatment trial for Covid-19 with Russian pharma outfit Nearmedic International. It is in talks with eight pharma firms about using its facilities to mount a “human challenge” study on potential vaccine candidates. As such, it could play an integral part in bringing a vaccine to market quickly.

Normally, the efficacy of a vaccine candidate is tested in field studies, where the treatment and a placebo are given to thousands — or even tens of thousands — of people. Reseachers monitor those who get infected and how they react.

These phase III field studies are complex and time-consuming, and often the longest part of a vaccine’s development. With Covid-19, the focus of the health authorities and the public is to suppress the natural spread of the virus, which may frustrate the field study.

With a human challenge study, a small sample of people, perhaps 100 to 150 , are given the vaccine candidate or a placebo. All subjects are then infected with an attenuated strain of coronavirus a month later, and monitored in a quarantined environment for 10 days. Nir Eyal, director of the centre for population-level bioethics at Rutgers University in New Jersey, told Nature publication that human challenge studies could “greatly accelerate the time to approval and potential use” of a coronavirus vaccine.

The hVivo clinic has a virology laboratory and is one of only two such private facilities in Europe.

Friel said volunteers would be selected from the lowest-risk, healthiest cohorts. The clinic will have access to a full array of antiviral treatments, if necessary. “Over a three-month period, we can have 140 patients tested,” says Friel.

An ethical concern exists about challenging humans with even a weakened strain of a potentially deadly virus. Eyal says society lets “humans volunteer to do risky things” all the time. “We let people volunteer to be emergency medical services during this period. That significantly elevates their risk of getting infected.”

HVivo placed the call for volunteers for a coronavirus trial on its flucamp.com site on March 4. It has received 54,000 replies. “On a normal week we might get 20 to 40 volunteers,” says Friel. Volunteers get £3,500, but Friel says the motivation is not monetary. “It’s almost like contributing to the war effort.

pogue
28/4/2020
07:13
yep, ODX to rocket again today :-) LOL,,, GLA Holders, cheers Wan :-)
wanobi
28/4/2020
07:11
Eyes down Pharma Bingo call Omega (ODX) supply agreement RNS


RNS Number : 0470L
Omega Diagnostics Group PLC
28 April 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
VISITECT(R) CD4 Advanced Disease
Supply Agreement with Clinton Health Access Initiative, Inc.
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases, food intolerance and allergy testing, announces that it has signed a supply agreement ("Agreement") with Clinton Health Access Initiative, Inc. ("CHAI")(1) .
The objective of the Agreement is to accelerate access to Omega's VISITECT(R) CD4 Advanced Disease rapid test(2) in low-income countries, lower-middle income countries and upper-middle income countries (together "Eligible Countries") as classified by the World Bank. The VISITECT(R) CD4 Advanced Disease Test is the only currently available handheld lateral flow point of care test for identifying patients with advanced HIV who are at risk of potentially life-threatening opportunistic infections.
The Agreement runs until 31 December 2021, during which time CHAI, with support from Unitaid(3) , will procure up to a maximum of 500,000 VISITECT(R) CD4 Advanced Disease tests. Within 14 days of signing the Agreement, CHAI will place an initial purchase order for 100,000 tests with delivery dependent upon demand being confirmed by certain Eligible Countries. We expect demand to be confirmed by Eligible Countries later this quarter with shipment to follow thereafter.
The supply of VISITECT(R) CD4 Advanced Disease tests under the Agreement will help to inform Eligible Countries with national implementation planning to support routine use of the test.
Colin King, CEO of Omega commented: "We are pleased that Omega has been able to enter into this supply agreement with CHAI, who have been very supportive towards accelerating the availability of our VISITECT(R) CD4 Advanced Disease. This test will help support the healthcare needs of the many people in those countries that are most in need. "
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
(1) The Clinton Health Access Initiative, Inc. (CHAI) is a global health organisation committed to saving lives. CHAI works with partners to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems.
(2) VISITECT(R) CD4 Advanced Disease is a rapid, semi-quantitative lateral flow assay for the estimation of CD4 protein on the surface of CD4+ T cells in human whole blood that indicates whether the level is above or below 200 cells/L. It can be used in decentralised settings at the point-of-care or primary healthcare level, identifying those at risk of Opportunistic Infections and supporting diagnostic decision-making, particularly for patients living with advanced HIV disease.
(3) Unitaid is an international development agency that invests in innovations to prevent, diagnose and treat diseases including HIV/AIDS, hepatitis C, cervical cancer, tuberculosis and malaria more quickly, affordably and effectively. A growing number of Unitaid's programs address more than one disease, maximising the effectiveness of health systems.

pogue
28/4/2020
07:07
BUR results today. On the face of it, last year was quiet (which they have already told us) but the first few months of this year look incredible. But the figures are never easy to understand so I'm looking at the full report.
mad foetus
28/4/2020
07:05
Good morning all, Good luck and good health today, cheers Wan :-)
wanobi
28/4/2020
06:09
Rigger What has happened to Peter Schiffs voice over the years.I`m a big fan of his but sometimes his voice gets too much.He was a lot more relaxed back in the day though wasn't he! LOL
saint in exile
27/4/2020
22:49
thanx Rb, that's good to know, cheers Wan :-)
wanobi
27/4/2020
22:31
Wan you’re welcome, I’m enjoying going back listening to the guys that hooked me into commodities and miners myself.

As for Cheltenham fortunately not, all of us that went are still in fine fettle as far as we know; we also did Uttoxeter the next day, quite a few tend to travel up. We did early starts, travel down on the day, so maybe that helped a bit and used the sanitizer on hand.

riggerbeautz
27/4/2020
22:24
Rb, something that crossed my mind today and thankfully you dodged it,,,, but, did any of your mates get cv19 from Cheltenham,,, I hear many who attended did, is that correct??

cheers Wan :-)

wanobi
27/4/2020
22:22
many thanx Rb, another one for the morning,,, good job I'm up at 6 these days :-) LOL,,,, joking aside, I really do value the education you and others are giving me here,, so valuable,,,, many many thanx,,, cheers Wan :-)
wanobi
27/4/2020
22:19
Wan I’ve been full on bear porn since last week and another of my porn stars is Dave Skarica, about 10 years back he wrote a book the Great Commodity Super Cycle; he’s actually not so much about spreading fear, more about focusing on trading.

Anyhow, I had a listen to his latest musings and after about 3 minutes in he starts to touch on USO etf and how it works, gold/silver and the types of miners to follow and music to my thoughts gives reason for deflation then inflation in a bearish kind of way.


P.s it’s not that long only 14 mins

riggerbeautz
27/4/2020
22:12
many thanx Rb, I shall listen to that in the morning, for sure :-) Cheers Wan :-)
wanobi
27/4/2020
22:05
Dr Anthony Fauci - Director, US National Institute of Allergy and infection diseases, CNN Soundbite - 'word for word off the telebox tonight' - what you want, if you are going to immediately identify, isolate and contact trace a person so that you can quickly get them out of society and stop spreading to other people,, you want a test that you know the answer right away, one of the problems with tests that you get back several days later is that you generally let that person who might actually be infected go back into society and inadvertently be infecting other people while you're waiting for the result of the test,,, to really get the handle on those areas where they don't have a lot of infected individuals we want to effectively identify, isolate and contact trace,,,, you want the result of the test in REAL TIME, you want to know exactly what you are dealing with at the time you're dealing with it!!!!!!!!

Cheers
Wan :-)

wanobi
27/4/2020
21:26
Frustrating share price movement indeed. What do we expect the timeline of news to be over coming days/weeks?
skeptic1
Chat Pages: Latest  2895  2894  2893  2892  2891  2890  2889  2888  2887  2886  2885  2884  Older